240 related articles for article (PubMed ID: 29328435)
1. miR‑214 reduces cisplatin resistance by targeting netrin‑1 in bladder cancer cells.
Liu J; Bi J; Li Z; Li Z; Liu X; Kong C
Int J Mol Med; 2018 Mar; 41(3):1765-1773. PubMed ID: 29328435
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA‑214 suppresses the viability, migration and invasion of human colorectal carcinoma cells via targeting transglutaminase 2.
Shan H; Zhou X; Chen C
Mol Med Rep; 2019 Aug; 20(2):1459-1467. PubMed ID: 31173203
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA‑214 upregulates HIF‑1α and VEGF by targeting ING4 in lung cancer cells.
Li Y; Zhao L; Qi Y; Yang X
Mol Med Rep; 2019 Jun; 19(6):4935-4945. PubMed ID: 31059086
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of miR‑214 attenuates the migration and invasion of triple‑negative breast cancer cells.
Zhang Y; Zhao Z; Li S; Dong L; Li Y; Mao Y; Liang Y; Tao Y; Ma J
Mol Med Rep; 2019 May; 19(5):4035-4042. PubMed ID: 30942417
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway.
Wang F; Li L; Chen Z; Zhu M; Gu Y
Int J Mol Med; 2016 May; 37(5):1421-8. PubMed ID: 26951965
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-98 promotes drug resistance and regulates mitochondrial dynamics by targeting LASS2 in bladder cancer cells.
Luan T; Fu S; Huang L; Zuo Y; Ding M; Li N; Chen J; Wang H; Wang J
Exp Cell Res; 2018 Dec; 373(1-2):188-197. PubMed ID: 30463687
[TBL] [Abstract][Full Text] [Related]
7. Derlin-1 overexpression confers poor prognosis in muscle invasive bladder cancer and contributes to chemoresistance and invasion through PI3K/AKT and ERK/MMP signaling.
Dong Q; Fu L; Zhao Y; Tan S; Wang E
Oncotarget; 2017 Mar; 8(10):17059-17069. PubMed ID: 28178653
[TBL] [Abstract][Full Text] [Related]
8. Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation.
Li X; Wang H; Wang J; Chen Y; Yin X; Shi G; Li H; Hu Z; Liang X
BMC Cancer; 2016 Aug; 16():578. PubMed ID: 27485374
[TBL] [Abstract][Full Text] [Related]
9. MiR-1/GOLPH3/Foxo1 Signaling Pathway Regulates Proliferation of Bladder Cancer.
Liu MK; Ma T; Yu Y; Suo Y; Li K; Song SC; Zhang W
Technol Cancer Res Treat; 2019; 18():1533033819886897. PubMed ID: 31714185
[TBL] [Abstract][Full Text] [Related]
10. miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.
Lei Y; Li B; Tong S; Qi L; Hu X; Cui Y; Li Z; He W; Zu X; Wang Z; Chen M
PLoS One; 2015; 10(2):e0117809. PubMed ID: 25658842
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-294 Promotes Cellular Proliferation and Motility through the PI3K/AKT and JAK/STAT Pathways by Upregulation of NRAS in Bladder Cancer.
Li Y; Shan Z; Liu C; Yang D; Wu J; Men C; Xu Y
Biochemistry (Mosc); 2017 Apr; 82(4):474-482. PubMed ID: 28371605
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-325 Is a Potential Biomarker and Tumor Regulator in Human Bladder Cancer.
Lin T; Zhou S; Gao H; Li Y; Sun L
Technol Cancer Res Treat; 2018 Jan; 17():1533033818790536. PubMed ID: 30176759
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol induces apoptosis of bladder cancer cells via miR‑21 regulation of the Akt/Bcl‑2 signaling pathway.
Zhou C; Ding J; Wu Y
Mol Med Rep; 2014 Apr; 9(4):1467-73. PubMed ID: 24535223
[TBL] [Abstract][Full Text] [Related]
14. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
15. The role of c-FLIP in cisplatin resistance of human bladder cancer cells.
Lee S; Yoon CY; Byun SS; Lee E; Lee SE
J Urol; 2013 Jun; 189(6):2327-34. PubMed ID: 23313194
[TBL] [Abstract][Full Text] [Related]
16. MiR-194 inhibits cell proliferation and invasion via repression of RAP2B in bladder cancer.
Zhang M; Zhuang Q; Cui L
Biomed Pharmacother; 2016 May; 80():268-275. PubMed ID: 27133066
[TBL] [Abstract][Full Text] [Related]
17. HIF-1α/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer.
Sun Y; Guan Z; Liang L; Cheng Y; Zhou J; Li J; Xu Y
Oncol Rep; 2016 Mar; 35(3):1549-56. PubMed ID: 26717965
[TBL] [Abstract][Full Text] [Related]
18. TCF21 inhibits proliferation and chemoresistance through the AKT pathway in human gastric cancer.
Yang Z; Jiang X; Li D; Dong Q; Zhao H; Jiang X
Gene; 2019 Jan; 682():42-49. PubMed ID: 30296564
[TBL] [Abstract][Full Text] [Related]
19. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
[TBL] [Abstract][Full Text] [Related]
20. EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
Okamura S; Yoshino H; Kuroshima K; Tsuruda M; Osako Y; Sakaguchi T; Yonemori M; Yamada Y; Tatarano S; Nakagawa M; Enokida H
BMC Cancer; 2021 Jan; 21(1):48. PubMed ID: 33430801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
